Literature DB >> 9487245

Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis.

C C Bunn1, C P Denton, X Shi-Wen, C Knight, C M Black.   

Abstract

Sera from 735 patients with systemic sclerosis were classified according to antinuclear antibody (ANA) pattern as follows: centromere (25%), homogeneous (26%), fine speckled (21%), fine speckled with nucleolar (14%), coarse speckled (7%), nucleolar only (3%) and cytoplasmic only (3%). Immunoprecipitations using 35S-labelled HeLa cell antigen extract were performed using sera from 374 of these patients to detect the systemic sclerosis-specific antibodies to RNA polymerases I and III. The sera were selected to represent each ANA group, but focused on those giving fine speckled nucleoplasmic staining (with or without nucleolar staining) where all 86 sera positive for these antibodies were concentrated. Immunoprecipitates from a further 93 sera from patients with ANA-positive autoimmune diseases other than systemic sclerosis did not precipitate RNA polymerases. In addition, all sera were tested for antibodies to the extractable nuclear antigens topoisomerase I, nRNP, Ro, La and PM-Scl. Sera positive for antibodies to these antigens gave clear correlations with ANA patterns but, of the examples tested, none contained antibodies precipitating RNA polymerase I or III. Thus, sera containing antibodies to RNA polymerases I and III were exclusive of both anticentromere and anti-topoisomerase I, and formed a major serological subgroup (11.7%). Clinically, 77% were patients with diffuse cutaneous disease reflected by higher skin scores and a significantly higher incidence of renal involvement (33%) than patients with antibodies to topoisomerase I (3%).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9487245     DOI: 10.1093/rheumatology/37.1.15

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  44 in total

Review 1.  Systemic sclerosis: an autoantibody mosaic.

Authors:  C C Bunn; C M Black
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

Review 2.  Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.

Authors:  T Dick; R Mierau; P Bartz-Bazzanella; M Alavi; M Stoyanova-Scholz; J Kindler; E Genth
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

Review 3.  Combination therapies for systemic sclerosis.

Authors:  C P Denton; C M Black
Journal:  Springer Semin Immunopathol       Date:  2001

4.  Non-invasive measurement of biomechanical skin properties in systemic sclerosis.

Authors:  A Balbir-Gurman; C P Denton; B Nichols; C J Knight; A M Nahir; G Martin; C M Black
Journal:  Ann Rheum Dis       Date:  2002-03       Impact factor: 19.103

Review 5.  Evidence-based management of rapidly progressing systemic sclerosis.

Authors:  Dinesh Khanna; Christopher P Denton
Journal:  Best Pract Res Clin Rheumatol       Date:  2010-06       Impact factor: 4.098

Review 6.  Scleroderma renal crisis: new insights and developments.

Authors:  Elisa Y Rhew; Walter G Barr
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

7.  Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis.

Authors:  C Rigamonti; L M Shand; M Feudjo; C C Bunn; C M Black; C P Denton; A K Burroughs
Journal:  Gut       Date:  2005-09-08       Impact factor: 23.059

8.  HLA-DRB1*0407 and *1304 are risk factors for scleroderma renal crisis.

Authors:  Binh Nguyen; Maureen D Mayes; Frank C Arnett; Deborah del Junco; John D Reveille; Emilio B Gonzalez; Hilda T Draeger; Marilyn Perry; Amir Hendiani; Kiran K Anand; Shervin Assassi
Journal:  Arthritis Rheum       Date:  2011-02

Review 9.  Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?

Authors:  Chandra Mohan; Shervin Assassi
Journal:  BMJ       Date:  2015-11-26

10.  IgG from patients with systemic sclerosis bind to DNA antitopoisomerase 1 in normal human fibroblasts extracts.

Authors:  Mathieu C Tamby; Amélie Servettaz; Nicolas Tamas; Joseph Reinbolt; Frédéric Caux; Olivier Meyer; Yannick Allanore; André Kahan; Loïc Guillevin; Luc Mouthon
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.